Important Research Info

Celgene Corporation has just enrolled its 100th patient with Complex Regional Pain Syndrome in its national Lenalidomide research study. This study is very important to the CRPS community. If this study is completed and recruits 180 patients, other pharmaceutical corporations might also conduct national multicenter, double-blind, placebo-controlled studies.

Individuals who are currently taking medication do not need to discontinue it--"Opioid analgesics, non-opioid analgesics, non-steroidal anti-inflammatory drugs, anticonvulsants, antidepressant drugs and other non-drug therapies may be continued provided that the subject is on stable doses/regimens for at least four weeks prior to the start of the Treatment Phase (Visit 2)."

Learn more about this study and whether a study site is near you:
http://rsds.org/3/research/celgene.html

More information:
http://rsds.org/3/research/index.html